Navigation Links
Nastech Pharmaceutical Company Initiates Plan for Corporate Restructuring and Will Concentrate on Phase 2 Clinical Programs
Date:11/13/2007

Company to Host Webcast and Conference Call

BOTHELL, Wash., Nov. 13 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. ("Nastech") (Nasdaq: NSTK) announced today its corporate restructuring initiatives aimed at reducing operating expenses and enhancing shareholder value. Nastech will seek to establish its subsidiary, MDRNA, Inc., as an independent, separately financed company as was announced today, and will concentrate on Phase 2 clinical and partnered programs as well as cost containment strategies for the near-term.

"The steps that Nastech is taking will better position the Company to achieve our near-term goals as well as reduce our operational expenses while ensuring that we retain our key capabilities for long-term growth," stated Steven C. Quay, M.D., Ph.D., Chairman, President and CEO of Nastech. "The establishment of MDRNA as an independent company will better serve our shareholders by providing a structure that will help unlock the value of Nastech's RNAi assets as well as expedite the development of new therapeutics based on this exciting new technology. Furthermore, by having Nastech concentrate on our core drug delivery technologies and our most advanced clinical programs it will enable us to make the greatest progress with the resources that are available."

First, Nastech plans to concentrate its resources on its Phase 2 clinical development programs that are currently ongoing or planned including PYY3-36 Nasal Spray for obesity, Insulin Nasal Spray for type 2 diabetes, and PTH1-34 Nasal Spray for osteoporosis.

Secondly, as announced today, Nastech will move forward with the process of establishing MDRNA as an independent company. The new structure will giv
'/>"/>

SOURCE Nastech Pharmaceutical Company Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Nastech Pharmaceutical Company Announces Promotion of Rick Costantino, Ph.D., to Chief Scientific Officer of Delivery
2. Nastech Pharmaceutical Company Announces the Jeffrey Wenig Memorial Award for Outstanding Achievement in Drug Delivery
3. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
10. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
11. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... by HIV/AIDS in South Africa may provide insight on ... issues in other areas of the world, which may ... could lead to successful interventions. , A report ... Nations mentions that due to the HIV/AIDS pandemic, which ... children are at an increased risk for mental health ...
(Date:4/14/2014)... and American Associations for Dental Research (IADR/AADR) have ... Their Dental, Oral, and Craniofacial Manifestations." The complete ... Burke, Alison M. Boyce, Michael Collins, Brian L. ... Scott Ramnitz, Martha J. Somerman and J. Timothy ... the IADR/AADR Journal of Dental Research ...
(Date:4/14/2014)... IL A new study shows that moderate to ... increased risk of stroke, cancer and death. , Results ... moderate to severe obstructive sleep apnea were four times ... four times more likely to have a stroke (HR ... cancer (HR = 3.4), and 2.5 times more likely ...
(Date:4/14/2014)... 10, 2014. John DeLuca, PhD, and Yael Goverover, PhD, ... study how persons with multiple sclerosis (MS) perform everyday ... Reality to Measure Everyday Life Functional Activity in Multiple ... DeLuca is senior VP of Research & Training at ... York University, is a visiting scientist at Kessler Foundation. ...
(Date:4/14/2014)... a UT Dallas study involving serious youth offenders, the answer ... the next seven years: "How long do you think you,ll ... future encourages offending over time., Author Dr. Alex Piquero said ... life ahead of them offend at very high rates and ... to die much later in life offend much less., "In ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Rare bone diseases and their dental, oral and craniofacial manifestations 2Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2
... ... in Europe to Treat Neovascular AMD Patients with New Epimacular Brachytherapy System , ... Fremont, CA and Pisa, ... patients have been treated following the commercialization of the VIDON® ANV® Therapy System, the ...
... 12 Zimmer Holdings, Inc. (NYSE: ... the Securities and Exchange Commission an automatic shelf registration statement on ... of equity and debt securities and that it intends, subject to ... a benchmark size. , The Company intends to use the ...
... PARI Respiratory Equipment launched a newly ... Efficient Aerosol Delivery, rounding out their free learning ... case managers, and pharmacists. The updated class ... for caregivers to update their skills and receive ...
... 12 Bausch & Lomb, the global eye health company, ... Board of Directors. , Mr. Hassan was chairman and ... Merck & Co., Inc. on November 3. Before joining Schering-Plough, ... chairman and CEO (from 2001 to 2003) of Pharmacia Corporation ...
... cancer cells in lab study , THURSDAY, Nov. 12 (HealthDay ... leukemia holds promise as a possible treatment for ovarian cancer, ... used to treat chronic myeloid leukemia. Researchers at the University ... the growth and invasive powers of ovarian cancer cells. ...
... , ... Nikolai Tankovich, MD, Ph.D., President and Chief Medical Officer of Stemedica Cell Technologies, ... Science and Society at Trinity College, a constituent college of the University of ... for stem cells, was attended by more than 300 professors and staff representing ...
Cached Medicine News:Health News:NeoVista, Inc. Announces First Neovascular AMD Patient Treated with VIDION ANV Therapy System in Europe Following Commercialization 2Health News:NeoVista, Inc. Announces First Neovascular AMD Patient Treated with VIDION ANV Therapy System in Europe Following Commercialization 3Health News:Zimmer Holdings, Inc. Announces Offering of Senior Notes 2Health News:PARI Respiratory Equipment Offers New Respiratory Management Course 2Health News:Fred Hassan Joins Bausch & Lomb Board of Directors 2Health News:Leukemia Drug May Help Some Ovarian Cancer Patients 2Health News:Stemedica President Invited To Lecture At The University Of Oxford 2Health News:Stemedica President Invited To Lecture At The University Of Oxford 3
(Date:1/15/2014)... 15, 2014  Manufacturers, suppliers and distributors ... be able to protect their most important ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) ... Medical Device Industry, it steadfastly remains one ... cases involving IP infringement. This litigious nature ...
(Date:1/15/2014)... GENEVA, Ill. , Jan. 15, 2014 /PRNewswire-USNewswire/ ... been certified as a Medical Fitness Center by ... medically integrated health and fitness centers to achieve ... Center is the only certified fitness center in ... area. "The certification means the Cadence ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ... aspects in today,s growth in the pharmaceutical ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Perrigo Company (Nasdaq: PRGO ; TASE) today announced ... fiscal 2010 on Monday, November 2, 2009 at approximately 8:00 ... at 10:00 a.m. (ET) hosted by Joseph C. Papa, Perrigo,s ... be available live via webcast to interested parties on the ...
... As previously announced, WebMD Health Corp. (Nasdaq: WBMD ) ... Annual Meetings of Stockholders beginning at 9:30 a.m. Eastern Time on ... of the meetings will be available over the Internet. To listen ... www.wbmd.com (in the Investor Relations section) or at ...
Cached Medicine Technology:WebMD and HLTH Corporation to Webcast Annual Meetings of Stockholders 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: